We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
Read MoreHide Full Article
ImmuCell Corporation (ICCC - Free Report) delivered another quarter of sales growth in the second quarter of 2026, supported by healthy domestic demand and improved product availability. The animal-health company announced preliminary, unaudited second-quarter 2026 sales of $7.2 million, reflecting an 11.5% year-over-year increase. The rally was primarily fueled by a strong U.S. market, which more than offset softer international performance.
Management noted that the latest quarter was measured against a challenging comparison period in 2025, when distributors had significantly replenished inventories after prolonged supply shortages. Despite that difficult base, the company continued to expand sales, highlighting sustained customer demand and operational improvements.
Domestic Business Remains Key Growth Engine
ImmuCell's domestic sales reached $6.2 million during the quarter, representing a 27.7% increase from the prior-year period. The company attributed the strong performance to consistent demand across its product portfolio and improved product availability, allowing it to better serve dairy producers throughout the United States.
President and CEO Olivier te Boekhorst said that the company concentrated its commercial efforts on year-round dairy operations, a customer segment that tends to be more price sensitive. These initiatives, combined with an expanded sales organization, helped attract customers while strengthening relationships with the existing ones.
International sales, however, declined 38.9% year over year to $1 million. Management indicated that the decline largely reflected shipment timing rather than weakening end-user demand, particularly in Canada, where customer interest continues to remain healthy.
Product Portfolio Continues to Deliver Solid Growth
Sales growth was broad-based across ImmuCell's leading calf-health products. Revenues from Tri-Shield First Defense, the company's flagship calf-scours prevention product, increased 8.3% year over year to $4.9 million. Meanwhile, sales of Dual-Force and other products rose 19.1% to $2.3 million, reflecting continued market acceptance across the company's broader product portfolio.
Management emphasized that improved manufacturing capacity has enabled the company to capitalize on favorable market demand while supporting customer acquisition efforts.
1H Sales Maintain Strong Momentum
The positive quarterly performance also strengthened ImmuCell's first-half results. For the six months ended June 30, 2026, total product sales climbed 20.9% year over year to $17.5 million. Domestic revenues increased 32.5% to $16 million, while international sales fell 35.7% to $1.6 million.
Within the product lineup, Tri-Shield First Defense generated $12.8 million in first-half sales, representing a 25.1% increase year over year, whereas Dual-Force and other products contributed $4.8 million, up 10.9% from the prior-year period.
Looking Ahead
ImmuCell is scheduled to report complete second-quarter 2026 financial results and discuss the drivers behind its performance during its earnings conference call on Aug. 14, 2026. Investors will likely focus on whether the company can sustain its domestic sales momentum, continue improving manufacturing efficiency and gradually restore international growth in the coming quarters.
View the Zacks #1 Rank List
Image: Bigstock
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
ImmuCell Corporation (ICCC - Free Report) delivered another quarter of sales growth in the second quarter of 2026, supported by healthy domestic demand and improved product availability. The animal-health company announced preliminary, unaudited second-quarter 2026 sales of $7.2 million, reflecting an 11.5% year-over-year increase. The rally was primarily fueled by a strong U.S. market, which more than offset softer international performance.
Management noted that the latest quarter was measured against a challenging comparison period in 2025, when distributors had significantly replenished inventories after prolonged supply shortages. Despite that difficult base, the company continued to expand sales, highlighting sustained customer demand and operational improvements.
Domestic Business Remains Key Growth Engine
ImmuCell's domestic sales reached $6.2 million during the quarter, representing a 27.7% increase from the prior-year period. The company attributed the strong performance to consistent demand across its product portfolio and improved product availability, allowing it to better serve dairy producers throughout the United States.
President and CEO Olivier te Boekhorst said that the company concentrated its commercial efforts on year-round dairy operations, a customer segment that tends to be more price sensitive. These initiatives, combined with an expanded sales organization, helped attract customers while strengthening relationships with the existing ones.
International sales, however, declined 38.9% year over year to $1 million. Management indicated that the decline largely reflected shipment timing rather than weakening end-user demand, particularly in Canada, where customer interest continues to remain healthy.
Product Portfolio Continues to Deliver Solid Growth
Sales growth was broad-based across ImmuCell's leading calf-health products. Revenues from Tri-Shield First Defense, the company's flagship calf-scours prevention product, increased 8.3% year over year to $4.9 million. Meanwhile, sales of Dual-Force and other products rose 19.1% to $2.3 million, reflecting continued market acceptance across the company's broader product portfolio.
Management emphasized that improved manufacturing capacity has enabled the company to capitalize on favorable market demand while supporting customer acquisition efforts.
1H Sales Maintain Strong Momentum
The positive quarterly performance also strengthened ImmuCell's first-half results. For the six months ended June 30, 2026, total product sales climbed 20.9% year over year to $17.5 million. Domestic revenues increased 32.5% to $16 million, while international sales fell 35.7% to $1.6 million.
Within the product lineup, Tri-Shield First Defense generated $12.8 million in first-half sales, representing a 25.1% increase year over year, whereas Dual-Force and other products contributed $4.8 million, up 10.9% from the prior-year period.
Looking Ahead
ImmuCell is scheduled to report complete second-quarter 2026 financial results and discuss the drivers behind its performance during its earnings conference call on Aug. 14, 2026. Investors will likely focus on whether the company can sustain its domestic sales momentum, continue improving manufacturing efficiency and gradually restore international growth in the coming quarters.